OVERVIEW
According to WHO data, there are up to 8,000 rare diseases, most of which of genetic origin, which afflict more than 400 million people worldwide, of which about 60 million European and American citizens.
STATE OF THE ART
Today we are seeing an increasing demand for testing of a larger number of genes with two problems: lack of time to dedicate to complex cases and that 71% of laboratories in USA are close to full capacity.
Also, globally 50% of new patients are children and 30% won’t live to see their 5th Birthday. That’s happening because the clinical process in the field of rare diseases is hard, because a lot of stakeholders are unable to share information, documents and materials, so transforming the process long, from months to years to diagnose a genetic disease, generating a high rate of errors.
AIM
We accelerate the diagnosis process for rare genetic disease, supporting clinicians and researchers with Digital MedTech solutions to improve the quality life of patients and their families. We are a lighthouse to rescue from the Odyssey of genetic diseases.
We decided to found our startup in accordance with the last market forecast where the global market value of genomics is about € 80 B by 2027 and considering that Italy is the first country in Europe for the number of scientific publications in genomics.
WHO WE ARE
We are a Digital MedTech that developed JuliaOmix™ (www.juliaomix.com) a digital ecosystem to support the clinical decision for rare genetic disease.
The startup was founded in 2017 and up to date raised € 3M in equity funding. Today the team is composed by 25 people based in Rome (Italy).
OUR OFFER
We offer digital various services in cloud (SaaS) for hospitals and genetic laboratories, sold with a model of pay-per-analysis or license to: (a) collect health data of patients, (b) track the laboratory workflow and (c ) support the genetic diagnosis.
WHY US
We are an Italian tribe of innovators and visionary experts in bioinformatics and genetics that work in the most important European country in research and development for genetics.
CHALLENGES
We are in the scaling up stage and our goal is to move to new European countries, USA and Australia in the next three years. For this reason we are looking for new international investors to support our growth in the market.
PERSPECTIVES
We want to be a lighthouse that rescue from the Odyssey of genetic diseases. In Italy we are developing the global reference for the diagnosis of genetic and rare diseases for advanced diagnostics, experimental and industrial research, precision medicine and advanced therapies, reception of patients and families.
